Therapeutics and Pharmacogenetics of Brolucizumab and Other Anti-VEGF Agents in Treating Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy – Deep Learning towards Precision Medicine (ChiCTR) - Oct 16, 2026 - P=N/A | N=3200 | Recruiting | Sponsor: Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong; Department of Ophthalmology and Visual Sciences, The Chinese Uni | Not yet recruiting ➔ Recruiting | Phase classification: P3 ➔ PN/A | N=864 ➔ 3200
Enrollment change • Enrollment open • Phase classification • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
|